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Destination shapes antibiotic resistance
gene acquisitions, abundance increases,
and diversity changes in Dutch travelers
Alaric W. D’Souza1† , Manish Boolchandani1† , Sanket Patel1,2, Gianluca Galazzo3 , Jarne M. van Hattem4 ,
Maris S. Arcilla5, Damian C. Melles5, Menno D. de Jong4 , Constance Schultsz4,6 , COMBAT Consortium,
Gautam Dantas1,2,7,8* and John Penders3,9*

Abstract
Background: Antimicrobial-resistant bacteria and their antimicrobial resistance (AMR) genes can spread by
hitchhiking in human guts. International travel can exacerbate this public health threat when travelers acquire AMR
genes endemic to their destinations and bring them back to their home countries. Prior studies have demonstrated
travel-related acquisition of specific opportunistic pathogens and AMR genes, but the extent and magnitude of
travel’s effects on the gut resistome remain largely unknown.
Methods: Using whole metagenomic shotgun sequencing, functional metagenomics, and Dirichlet multinomial
mixture models, we investigated the abundance, diversity, function, resistome architecture, and context of AMR
genes in the fecal microbiomes of 190 Dutch individuals, before and after travel to diverse international locations.
Results: Travel markedly increased the abundance and α-diversity of AMR genes in the travelers’ gut resistome, and
we determined that 56 unique AMR genes showed significant acquisition following international travel. These
acquisition events were biased towards AMR genes with efflux, inactivation, and target replacement resistance
mechanisms. Travel-induced shaping of the gut resistome had distinct correlations with geographical destination,
so individuals returning to The Netherlands from the same destination country were more likely to have similar
resistome features. Finally, we identified and detailed specific acquisition events of high-risk, mobile genetic
element-associated AMR genes including qnr fluoroquinolone resistance genes, blaCTX-M family extended-spectrum
β-lactamases, and the plasmid-borne mcr-1 colistin resistance gene.
(Continued on next page)
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Conclusions: Our results show that travel shapes the architecture of the human gut resistome and results in AMR
gene acquisition against a variety of antimicrobial drug classes. These broad acquisitions highlight the putative risks
that international travel poses to public health by gut resistome perturbation and the global spread of locally
endemic AMR genes.
Keywords: Resistome, Antibiotic resistance, Travel, mcr-1, β-Lactamases, ESBL

Background
Antimicrobial resistance (AMR) is a major global public
health threat with a high mortality cost [1–6]. AMR bacterial infections now frequently render antibiotics ineffective and limit clinicians’ antibiotic treatment options.
This trend threatens 70 years of progress in treating bacterial infectious diseases.
AMR is rising worldwide, but there are large geographic differences in the prevalence and type of resistant bacteria and their AMR genes [7, 8]. Low- and
middle-income countries generally have higher endemic
AMR than high-income countries, mainly driven by antibiotic overuse in humans and animals [6–10]. International travel can facilitate the transfer of resistant
bacteria and AMR genes from their endemic regions to
other locations around the globe [11–18].
An AMR gene’s ability to spread via international
travel is context-dependent [11, 19, 20]. Context includes the AMR gene’s prevalence in the endemic region, the specific bacteria harboring the AMR gene, and
the other genetic elements colocalized with the gene.
AMR genes such as extended-spectrum β-lactamases
(ESBLs), qnr, and mcr-1 are often associated with mobile
genetic elements like plasmids and are of particularly
high concern due to their ease of spread [8, 11, 21–23].
Returning travelers are rarely tested for resistant bacteria or AMR genes unless they manifest clinical symptoms, so the magnitude of AMR gene acquisition risk
from international travel remains underdetermined.
Using microbial culture, studies have shown significant
acquisition rates of opportunistic pathogens, such as
ESBL-producing Enterobacteriaceae [16, 18, 24, 25].
These studies identified specific pathogenic bacteria acquired during international travel, and several identified
specific AMR genes acquired during travel [16, 26, 27].
But the effect of international travel on AMR is most
likely not limited to opportunistic pathogens such as
Escherichia coli or to ESBL-encoding resistance genes. A
broader risk assessment must include acquired commensals and their potential horizontal transfer of AMR genes
with host microbiomes.
Rapid advancements in sequencing technology, bioinformatics, and database curation facilitate quantitative
insight into the human microbiome’s role as an AMR
reservoir in a broader context and how this role might

be influenced by international travel [8, 28]. We can sequence all extracted DNA using shotgun metagenomic
sequencing [8, 28, 29], and we can directly identify AMR
genes in these shotgun metagenomes by mapping reads
to curated AMR gene databases [8, 28]. Though AMR
gene databases and identification techniques have made
significant advancements in recent years, they still rely
heavily on the traditional microbiological culture that
excludes many bacteria [28]. Functional metagenomics is
a powerful complementary method to more broadly survey AMR determinants without relying on culturing resistant bacteria [8, 28, 30]. Instead, functional
metagenomics uses a cultivable indicator bacterium to
identify functional AMR determinants from metagenomic samples via recombinant gene expression and
phenotypic selection [30].
Here, we combine next-generation sequencing, functional metagenomics, and statistical modeling to investigate the abundance, diversity, function, context, and
acquisition of AMR genes in a group of international
travelers. Our results demonstrate that international
travel is a significant perturbation to the gut resistome
and reveal destination-specific changes to travelers’
resistomes including AMR gene acquisitions against last
resort antibiotics and AMR gene colocalization with mobile genetic elements. These findings further our understanding of the role of travelers as potential reservoirs
and spreaders of AMR.

Methods
Study design, sample collection, and DNA extraction

Samples for this project were selected from a subset of
the broader Carriage Of Multiresistant Bacteria After
Travel (COMBAT) study [17, 31]. Within this multicenter longitudinal cohort study, travelers were recruited at
the outpatient travel clinics run by the Academic Medical Center (Amsterdam, The Netherlands), Havenziekenhuis (Rotterdam, The Netherlands), and Maastricht
University Medical Center/Public Health Service South
Limburg (Maastricht, The Netherlands). Minors, incapacitated subjects, and subjects that traveled abroad for
shorter than 1 week or longer than 3 months were excluded from the study. In total, 2001 travelers were included and provided with fecal swab kits that included
instructions, a modified Carey-Blair transport medium

D’Souza et al. Genome Medicine

(2021) 13:79

with an associated swab (Fecal Swab®; Copan, Brescia,
Italy), a questionnaire, and paid postage. Before leaving
for and immediately after returning from travel, subjects
took samples from their stool using the fecal swab kits
and mailed them to the lab. The methods for sample
collection are described in detail in Arcilla et al. [31] and
Arcilla et al. [17].
For the purpose of the present study, we limited the
selection to travelers to Southeastern Asia, South Asia,
North Africa, and Eastern Africa to have sufficient numbers per subregion. Subregions are defined according to
the United Nations regional grouping M49 standard
[32]. Travelers were excluded if they visited multiple
subregions or consumed antibiotics in the 3 months before travel. Selections were made by stratified random
sampling using SPSS.
Metagenomic DNA was extracted from stool samples
using repeated bead-beating (RBB) combined with
column-based purification according to protocol Q
(IHMS_SOP 06 V2 - http://www.microbiome-standards.
org/index.php?id=253) of the International Human
Microbiome Standards consortium [33]. Bead-beating
was done using the FastPrep™ Instrument (MP Biomedicals, Santa Ana, CA, USA) with 0.1-mm zirconium-silica
beads (BioSpec Products, Bartlesville, OK, USA) to
homogenize feces. DNA was finally purified by adapting
to the QIAamp DNA Stool Mini kit columns (Qiagen,
Hilden, Germany). A Qubit® fluorometer dsDNA HS
Assay (Invitrogen) was used to quantify extracted DNA,
and this DNA was stored at −20°C.
Extracted metagenomic DNA was diluted to 0.5 ng/μL
and prepared for sequencing with a Nextera DNA Library Prep Kit (Illumina) using a modified Nextera
protocol [34]. Libraries were purified using the Agencourt AMPure XP system (Beckman Coulter) and quantified using the Quant-iT PicoGreen dsDNA assay
(Invitrogen). For each sequencing lane, 10 nM of approximately 96 samples was pooled three independent
times. These pools were quantified using the Qubit®
dsDNA BR Assay and combined in an equimolar fashion. Samples were submitted for 2×150 bp paired-end
sequencing on an Illumina NextSeq High-Output platform with a target sequencing depth of 5 million reads
per sample.
Sequence quality filtering

Trimmomatic v0.36 [35] was used to trim Nextera
adapter sequences and to quality filter sequenced reads
with the following parameters:
Adapter = Nextera
Illuminaclip = 2:30:10:1:TRUE
Leading = 10
Traling = 10
Sliding window =4:15
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Min length = 60
Deconseq v0.4.3 was used to remove human read contamination [36].
Functional metagenomics

We constructed, sequenced, and analyzed 21 smallinsert (>0.7 kb) functional metagenomics libraries which
were screened for antibiotic resistance with adaptations
to our previously published protocols [30, 37–44]. The
experimental protocol for creation and screening of
functional metagenomics library is briefly described
below:
Construction of functional metagenomics libraries

The metagenomic DNA (mgDNA) of 190 post-travel
samples were divided based on four different travel regions, and up to ten random samples from each region
were pooled together for the construction of each functional metagenomic library (Additional file 1: Fig. S1).
The pooled mgDNA was fragmented by partial restriction digestion using BamHI, BglII, and BstYI (New England Biolabs (NEB)) restriction enzymes. First, 1 μg of
mgDNA was mixed with 1–5 units of both BamHI and
BglII (NEB) in a total volume of 90 μl. The digest was
put at 37 °C in an Eppendorf incubator, and aliquots of
15 μl were withdrawn after 5, 10, and 15 min and collected in an Eppendorf tube, containing 270 μl of absolute ethanol and 9 μl of 3M sodium acetate (pH=8) on
ice. After withdrawing the third aliquot, 1–5 units of restriction enzyme BstYI (NEB) was added to the
remaining digest. The incubation was continued at 37
°C, while withdrawing 15 μl every 5 min and pooling
with the first aliquots, on ice. The pooled sample was
mixed by vortexing and incubated at −70 °C for 5–10
min. The DNA was pelleted by centrifugating for 10 min
at full speed in an Eppendorf centrifuge and subsequently washed once with 200 μl of 80% ethanol. After
drying, the DNA pellet was dissolved in 50 μl of sterile
water.
For size selection and purification of the partially restriction digested mgDNA, the MagVigen™ DNA select
Kit (NVigen Inc.) was used according to the manufacturer’s instructions to retain fragments >700 bp. Finally,
the sample was eluted in 30 μl of sterile water, and DNA
concentration was quantified in a Qubit™ fluorometer
(Invitrogen).
Vector pZE21-MCS was linearized by digestion with
restriction enzyme BamHI and dephosphorylated using
alkaline phosphatase (FastAP Thermosensitive Alkaline
Phosphatase; Thermo Scientific), according to the manufacturer’s instructions. Ligation was performed using 50
ng of linearized, dephosphorylated pZE21-MCS vector
and 100–150 ng of fragmented, size-selected insert
DNA, according to the suppliers’ instructions (DNA
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ligation kit LONG; TaKaRa). Ligation reaction was performed for at least 3 h at 16 °C.
Subsequently, the ligation mixture was precipitated by
adding 5 μl of 3 M sodium acetate pH 8 and 150 μl of
absolute ethanol. The solution was mixed and incubated
for 10 min at −70 °C, followed by a spin at full speed for
10 min in an Eppendorf centrifuge. The resulting DNA
pellet was washed twice with freshly prepared 80% ethanol, air-dried, and dissolved in 5 μl sterile water. On ice,
25 μl of electrocompetent E. coli cells (E.cloni® 10G;
Lucigen) was added to the ligated plasmid DNA, and
electroporation was done according to the supplier’s instructions (1-mm cuvette, 10 μF, 600 Ω, 1800 V). Immediately after transformation, 2 ml of LB medium was
added to the cells, and the suspension was incubated for
1 hat 37 °C in an orbital shaker.
The library titers were determined by plating 0.1 μl
and 0.01 μl of recovered cells onto Luria-Broth (LB) agar
plates containing 50 μg/ml kanamycin as previously described [30].
The remainder of recovered cells were grown overnight in 50 ml of LB broth containing 50 μg/ml kanamycin (LB-Kan) in a shaker (library amplification).
The culture was then centrifuged and re-suspended in
15 ml LB-Kan broth containing 15% glycerol and stored
at −80 °C for subsequent screening.
Functional screening of antibiotic resistance

Each metagenomic expression library was screened on
Mueller-Hinton agar with 50 μg/ml kanamycin and one
of the 15 antibiotics at concentration listed in Additional
file 2: Table S9. Before plating each library on antibioticcontaining growth media, the concentration of each library was adjusted such that 100 μl of library freezer
stock contains at least 10× the total number of unique
clones as determined at the time of library creation. To
adjust the concentration, the freezer stock solution was
either diluted with MH-Kan or centrifuged and reconstituted again in the appropriate volume for plating. The
antibiotic selection plates were incubated for 16–24 h at
37°C to allow the growth of antibiotic-resistant clones.
Additionally, for each antibiotic selection, a negative
control plate of E. coli (E.cloni® 10G; Lucigen) transformed with unmodified pZE21 (without metagenomics
insert) was plated to ensure that the concentration of
antibiotic used entirely inhibited the growth of clones
with only pZE21. The surviving colonies from each antibiotic selection were collected by adding 1500 μl of LBKan with 15% glycerol and then gently scraped the colonies with an L-shaped spreader from the agar plate.
The slurry of antibiotic-resistant clones was removed
from the surface of the plate and then stored at −80 °C
before sequencing them with the Illumina NextSeq
platform.
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Sequencing, assembly, and annotation of antibiotic
resistance genes

The plasmid DNA-containing antibiotic-resistant
mgDNA fragments were extracted from functionally selected clones using the QIAprep Spin Miniprep Kit (Qiagen) and prepared for sequencing with a Nextera
protocol as described above. The samples were submitted for sequencing using an Illumina NextSeq platform
(2×150 bp reads). Reads from each antibiotic selection
were assembled into contigs using PARFuMS [37], a tool
specifically designed for high-throughput assembly of
resistant-conferring DNA fragments from functional selections. Of note, selections were excluded from analysis
if (i) the number of contigs assembled was 10 times
more than the total number of colonies or (ii) more than
200 contigs were assembled. Contigs were also filtered
based on length (> 500 bp).
The total number of contigs obtained was 7020, and in
total, 16,334 open reading frames (ORFs) were predicted
in these contigs using the gene finding algorithm Prodigal [45]. These ORFs were annotated following a hierarchical approach, where the ORFs were first searched
against BLAST-based ARG databases (CARD [46],
ResFinder [46], and AMRFinder-Prot [47]) with high
percent identity (>95%) and coverage (>95%), and then
the remaining ORFs were annotated using HMM-based
ARG databases (Resfams [48], AMRFinder-fam [47]).
This AMR gene annotator (resAnnotator.py) pipeline for
the sequential annotation of ARGs using BLAST and
HMM approach is available on GitHub. Overall, 1233
complete sequences were assigned using the resAnnotator.py pipeline. Percentage identity of 1233 ARGs was
examined via a BlastP query against both the NCBI protein Non-Redundant (NR) database (retrieved 10 January
2020) and a combined database of all ARG proteins
from CARD, NDARO to identify the top local alignment. The best hit identified using BlastP was then used
for a global alignment using the needle program with
the following non-default parameters: -gapopen-10
-gapextend=0.5. Twenty-two AMR genes did not have
any homologs in known AMR sequence databases.
Quantification of antibiotic resistance genes in
metagenomes

AMR gene relative abundance was quantified using
ShortBRED [49] v0.9.4. A ShortBRED marker database
was built from 7921 antibiotic resistance proteins that
were used as a protein of interest for the identification
of marker families using shortbred_identify.py. Default
parameters were used with the exception for -clustid
0.95 (see Additional file 1: Supplementary Note A for
more information on 95% sequence identity clustering).
Uniref90 [50] was the reference masking protein database (Additional file 1: Fig. S1). These protein sequences
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include ARG sequences from the Comprehensive Antibiotic Resistance Database (CARD) [46], the NCBI-AMR
database [47], and antibiotic resistance proteins identified using functional metagenomics in this cohort as well
as from previous studies [37–44, 51]. This resulted in a
database consisting of 6585 unique marker sequences
representing 2331 AMR gene families. These AMR gene
families were then manually curated, and the entries
with the following criteria were removed from analysis
consideration because they would not be confidently expected to provide resistance based solely on a short-read
marker (e.g., when that gene would require other components to provide phenotypic resistance, or when
short-read markers would not distinguish between susceptible vs resistant versions of an antibiotic target):
1) Genes associated with global gene regulators, twocomponent system proteins, and signaling mediators (e.g., blaZ, vanS-vanR, mecI, mepR, gadW,
marR)
2) Genes encoding subunits that are part of multiple
efflux pumps (e.g., tolC, oprM, opmD)
3) Resistance via mutation in genes (e.g., resistance to
antifolate drugs via mutations in dhfr, resistance to
rifamycin via mutation in rpoB)
4) Genes conferring resistance by modifying cell wall
charge (e.g., mprF)
5) Genes that reduce permeability (omp38, tmrB) or
confer resistance through overexpression (e.g.,
thymidylate synthase)
6) General efflux pumps that came through functional
selections (MFS-type, ABC-type)
The relative abundance of AMR gene families was
quantified by mapping reads to the filtered set of marker
sequences using shortbred_quantify.py. ShortBRED hits
were filtered out if they had counts lower than 2 or
mean reads per kilobase million (RPKM) lower than
0.001. The filtered list of markers is given in Additional
file 2: Table S8.
Metagenome profiling and assembly

Microbial taxa relative abundance was calculated using
MetaPhlAn2 [52] (repository tag 2.6.0). Contig assembly
was done using the de novo assembler SPAdes v3.14.0
[53]. Assemblies were annotated using our in-house
AMR gene annotator called resAnnotator.py which includes CARD [46], Resfinder [54], NCBI-AMR [47], and
Resfams [48]. Assemblies were also annotated with
Prokka [55]. The BLAST+ command line tool (blastn)
[56] was used to compare the mcr-1 plasmid to our contig containing mcr-1. FastANI [57] v1.3 was used for
average nucleotide identity comparisons between assembly GCA_004135815.1 (a CRE resistant E. coli isolated
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from stool from a patient with gastroenteritis in 2014 at
Maharaj nakorn Chiang Mai hospital) and our draft genome assembly and for comparisons between our assembled mcr-1 containing plasmid and NCBI Reference
Sequence NZ_CP034405.1 (a plasmid sequence from the
CRE resistant E. coli isolate). The BioSample for this isolate is SAMN10531954.
MGE element profiling

Annotations with the following keywords were pulled
from the functional metagenomic assemblies: transposase, transposon, integrase, integron, conjugative, conjugal, recombinase, recombination, mobilization, and
phage. These elements were counted as putative mobile
genetic elements. The same keywords were used in the
analysis of putative mobile genetic elements from whole
metagenome assemblies.
Comparisons to other shotgun metagenomic data

The cohort of 110 Indian residents we compared to was
published by Dhakan et al. in 2019 [58]. Fecal samples
from this cohort were frozen within 30 min of collection
and were subjected to whole metagenome shotgun sequencing. This cohort was selected because it includes a
wide age range (average age of 29.72 with a standard deviation of 17.41) and samples from North-Central and
South India, providing a more complete picture of the
resistome than studies focusing only a single area or age
range. Additionally, all travelers to South Asia in our
study visited India, making it the most appropriate comparison country for this study. The data from Dhakan
et al. can be accessed from BioProject PRJNA397112 or
from [https://doi.org/10.5524/100548].
Statistical analysis and data visualization

Statistical analysis was conducted in R [59] version 3.6.2.
Visualizations were made using ggplot2 [60] version
3.1.0, ggpubr [61] version 0.2.5, and cowplot [62] version
1.0.0. Figures 1 and 9b were made using sf [63] version
0.1.8 and spData [64] version 0.3.3 with post-processing
in Adobe Illustrator [65] version CC 2020 (24.0.2). Sankey networks were generated using networkD3 [66] version 0.4 with the sankeyNetwork function. Alignment
visualization for mcr-1 in Fig. 9c was made using genoPlotR [67]. Dirichlet multinomial mixture models [68]
were made using DirichletMultinomial [69] version
1.26.0. For each clustering model (all samples together,
only T0 samples, and only T1 samples), we did 50 iterations of clustering with different starting seeds. For each
of these 50 iterations, we started with 1 cluster and
stopped at a maximum of 25 clusters. Laplace approximations were generated for each cluster model, and the cluster model with the most evidence by this metric was
chosen for further analysis (see source data of Figs. 3b and

D’Souza et al. Genome Medicine

(2021) 13:79

Page 6 of 21

Fig. 1 Destinations for Dutch travelers. A total of 190 Dutch individuals’ gut microbiomes were sampled before and after traveling (380 total
samples) to 4 different subregions (Northern Africa, Eastern Africa, Southern Asia, and Southeastern Asia)

5b for AIC and Laplace approximations for all clustering
models). Samples were grouped with their best-matched
cluster (see source data of Figs. 3b and 5b for cluster
matching probability for each sample). Linear mixedeffects models were implemented with lme4 [70] version
1.1-21 (lmer function). Models were assessed using report
[71] version 0.1.0 and performance [72] version 0.4.4.
Vegan: Community Ecology Package [73] version 2.5.6
was used for the canonical analysis of principal coordinates [74] (capscale function), α- and β-diversity calculations (diversity and vegdist functions), and PERMANOVA
tests (anova.cca function). Dabestr [75] version 0.2.3 was
used for bootstrapping samples and calculating confidence
intervals from bootstrapped samples. Linear models were
implemented with lme4 [70] version 1.1.21 (lmer function). MaAsLin2 was used for modeling resistome data
with metadata and taxonomic variables [76]. Subject_ID
was used as a random effect for all models, and travel destination was also included as a random effect for the
model that included all other metadata variables. Confidence intervals for non-bootstrapped samples were calculated using Rmisc [77] version 1.5 (group.CI function).
Multinomial tests were calculated using the multinomial.test function from EMT [78] version 1.1. Stats (base
R) version 3.6.2 was used for statistical calculations. The
wilcox.test function was applied with paired=T/F as

appropriate. The fisher.test function was for Fisher’s exact
comparisons. The binom.test function was for binomial
tests. The p.adjust function was applied where appropriate
to correct for multiple hypothesis testing with method=
“fdr” (Benjamini-Hochberg [79]). p values lower than machine precision of 2.220446e−16 are reported as p<2e−16.
The aov function was used for the analysis of variance,
and the TukeyHSD function was used for the analysis of
variance significance testing. The sqrt function was used
for square root transformations. Log transformation was
implemented using a custom log function.
LOG <- function(x) {y <- replace(x, x == 0,
min(x[x>0])/2); return(log10(y))}

Results
Cohort description and generation of a functional
metagenomics augmented resistance marker database

To understand the effects of travel on the human gut
resistome, we conducted whole metagenome shotgun sequencing and analysis on fecal samples from 190 Dutch
individuals collected immediately before and after they
traveled internationally to 4 different geographic regions
(Fig. 1 and Additional file 2: Table S1). Our cohort visited Northern Africa (n=43), Eastern Africa (n=44),
Southern Asia (n=51), and Southeastern Asia (n=52),
yielding 380 samples (190 before travel and 190 after
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travel). A total of 174 study participants denied using
antibiotics during the observation period while 10 participants claimed antibiotic use (6 participants answered
unknown). The majority (n=170) were traveling on holiday, with a minority traveling for business (n=6), to visit
relatives (n=4), and for religious purposes (n=10). Participants were adults with a median age of 50.7 (IQR 32.5–
59.2) years.
To improve on AMR gene detection offered by conventional AMR databases, we used functional metagenomics. Functional metagenomics is a cultureindependent method for identifying AMR genes from a
metagenomic sample which, when expressed in a heterologous host, would enable this previously susceptible
host to gain phenotypic resistance to an antibiotic [30,
37–44, 80]. In our protocol, we shotgun-cloned metagenomic DNA into an expression vector and transformed
the resultant metagenomic expression libraries into E.
coli indicator hosts. These E. coli transformant libraries
were then screened against antibiotics at selective concentrations, and the cloned insert DNA in surviving
transformants was sequenced to identify open reading
frames that confer phenotypic resistance to the normally
susceptible host. Here, we refer to AMR genes identified
by this method as “functionally discovered AMR genes.”
We pooled our cohort stool samples within travel destinations to make 21 functional metagenomics libraries,
which we screened against 15 antibiotics (Additional file
1: Fig. S1 and Additional file 1: Supplementary Note A)
[30, 37]. These libraries yielded resistant transformants
for every antibiotic screened except meropenem. By
combining sequences from known AMR gene databases
(CARD [46], NCBI-AMRFinder [47]) and from our functionally discovered AMR genes, we generated a custom
ShortBRED [49] database with 6585 marker sequences
corresponding to 2331 AMR gene families.
Travel increases AMR gene abundance and α-diversity but
decreases β-diversity

We used our custom ShortBRED database to profile the
gut resistome in our 380 Dutch traveler samples. We
then compared the pre- and post-travel samples for
AMR gene abundance and diversity. AMR gene abundance in the gut microbiome was significantly higher
(p=1.8e−5 [paired sample t test]) in the post-travel compared to the pre-travel samples (Fig. 2a), indicating that
travel may enrich the microbiome for AMR determinants. This increase in abundance was matched by increased α-diversity (Fig. 2b) measured by unique AMR
genes (richness, p<2e−16 [paired sample t test]) and by
the evenness of AMR genes in the resistome (Shannon
index, p<3e−12 [paired sample t test]). These results
suggest that travelers are acquiring new AMR genes
abroad.
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Linear mixed-effects modeling of AMR gene abundance and α-diversity measured as richness (unique
genes) showed that while the two measurements are significantly related (p<0.001), pre- or post-travel state significantly impacts AMR α-diversity (p<0.001) even when
AMR gene abundance is accounted for (Additional file
2: Tables S2-S4 and Additional file 1: Supplementary
Note B). Time point also had a larger effect on αdiversity (measured as richness) than it did on resistance
gene abundance. These results are consistent with international travel as a driver of new AMR gene acquisition.
While AMR gene α-diversity increased following
travel, resistome β-diversity (Bray-Curtis dissimilarity)
between samples decreased (p<2e−16 [paired Wilcoxon
test]) (Fig. 2c). These results suggest that the pressure of
travel on the resistome may increase resistome similarity
between individuals despite their different destinations.
This finding could result from the acquisition of similar
AMR genes.
Unsupervised clustering separated pre- and post-travel
samples into distinct subclusters, suggesting composition
differences

Dirichlet multinomial mixture models [68], an unsupervised method for clustering and modeling metagenomics
data, revealed significant bias for samples from the same
collection time point to group in the same metaresistome (p<2e−16 [Fisher’s exact test]) (Fig. 3a). Each
metaresistome is a multinomial parameter probability
vector, fit from a Dirichlet prior, over the resistance
genes detected in our cohort. Together, the metaresistomes are the set of possible probability distributions
that could result in our 380 samples using multinomial
random draws. Thus, samples associated with the same
metaresistome can be thought of as being drawn from
the same underlying probability distribution.
Of the 8 metaresistomes in the best fit mixture model,
6 showed a significant bias to either the pre-travel (n=3)
or post-travel (n=3) time point (Fig. 3b). Since each subject has two samples, we determined if an individual’s
pre- and post-travel samples grouped in the same metaresistome. Instead, we observed 150 travelers (79%)
switched metaresistomes, indicating a travel-specific effect in addition to subject random effects.
Since we have underlying AMR gene probability distributions for each metaresistome in our final mixture
model, we can directly compare the models together.
The post-travel-biased metaresistomes were characterized by higher α-diversity and lower β-diversity (Additional file 1: Fig. S2), mirroring the results we observed
for the samples considered individually.
Prior studies of non-travel resistome perturbations [42,
81, 82] have used supervised clustering from Bray-Curtis
dissimilarity [74, 83] to determine the group significance
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Fig. 2 AMR gene abundance and α-diversity increases with travel and AMR gene β-diversity decreases. a The left panel shows the AMR gene
abundance in RPKM. Each point is a sample, and the boxes are the medians with interquartile ranges for the pre-travel samples in blue and the
post-travel samples in red. The p value (paired-sample t test) for the comparison is given at the top of the panel. The right panel shows the
difference between the bootstrapped distributions of the post- and pre-travel samples. The red line gives the 95% confidence interval for the
difference, and the point gives the estimate. b AMR gene α-diversity is measured by richness (top left panel), and Shannon Index (bottom left
panel) is compared between the pre-travel (blue) and post-travel (red) samples. Each point corresponds to a given sample, and each box gives
the median and interquartile range for the distribution. The p value (paired-sample t test) for the comparison is given at the top of each panel.
The panels to the right of the boxplots show the difference between the bootstrapped distributions of the post- and pre-travel samples. The red
line gives the 95% confidence interval for the difference and the point gives the estimate. c AMR gene β-diversity measured by Bray-Curtis
dissimilarity is compared between the pre-travel (blue) and post-travel (red) samples. Each point is a comparison between two samples within
the same time point group. The distributions are shown to the right of the points, and boxplots showing the median and interquartile ranges are
overlaid on top of the points. The p value by paired Wilcoxon test for the comparison is shown near the top. In the right panel, the lines show
the 95% confidence intervals, and points show the mean values for the pre- (blue) and post-travel (red) Bray-Curtis dissimilarity distributions.
Source data is provided in the source data file (Additional file 3)

to resistome composition. Supervised clustering of our
Dutch traveler resistomes also revealed significant separation (p=2e−4 [permanova]) between the pre-travel and
post-travel samples (Additional file 1: Fig. S3A). However, the 8 optimal metaresistomes from the Dirichlet
multinomial mixtures and the differences in the AMR
gene diversity between metaresistomes suggest subclusters exist within the pre-travel and post-travel time
points.
Destination-specific resistome signatures explain
metaresistome subclustering

Though all four destinations had increased AMR gene
abundance (Fig. 4a) and α-diversity (Fig. 4b), the magnitude of these differences varied and broadly agree with
clinical isolate resistance data published by the Center
for Disease Dynamics, Economics, and Policy (Additional file 2: Table S5 and Additional file 1: Supplementary Note C). Resistome α-diversity was significantly
higher for individuals returning from Southeastern Asia
than from the other three destinations (Additional file 1:
Fig. S4). Individuals traveling to the same subregion also
had decreased interindividual resistome β-diversity (p=
0.016 [unpaired Wilcoxon test]), suggesting that having

the same travel destination makes traveler resistomes
more similar (Additional file 1: Fig. S5 and Additional
file 1: Supplementary Note D). These β-diversity decreases were significantly larger in travelers returning
from Southeastern Asia and Eastern Africa than Northern Africa and Southern Asia (Fig. 4c). Thus, individuals
returning from Southeastern Asia and Eastern Africa
had more similar AMR profiles to other travelers to the
same destination than individuals returning from Northern Africa and Southern Asia.
To interrogate these region-specific effects, we rebuilt
Dirichlet multinomial mixture models after separating
the pre-travel and post-travel samples. Separating the
time points removes possible random effects due to subject identity allowing a narrower focus on destination.
This analysis yielded 9 metaresistomes (4 in the pretravel samples and 5 in the post-travel samples). Though
the pre-travel metaresistomes did not show significant
bias by destination (p=0.485 [Fisher’s exact test]), the
post-travel metaresistomes had a strong regional bias
(p<2e−16 [Fisher’s exact test]) (Fig. 5a). These results
also appeared in supervised clustering where destination
significantly distinguished samples (Additional file 1: Fig.
S3B-C) after travel (p=4e−4 [permanova]) but not before
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Fig. 3 Travel outweighs subject effects in shaping resistome architecture. a 95% confidence interval (red line segment), odds ratio (red point),
and p value calculated by Fisher’s exact test for samples with the same time point being drawn from the same metaresistome. The black vertical
line at 1 shows the expected result under the null. b Each row in this plot corresponds to a metaresistome (m1–m8) in a Dirichlet multinomial
mixture model of all traveler samples. The pie charts on the left are proportional in size to the number of samples in each metaresistome. The fill
of the chart corresponds to the number of individuals in the time point (pre-travel in blue and post-travel in red). The network shows the
number of individuals that transition from any model to any other model following their return from abroad. The black lines indicate staying
within the same model, and the green lines indicate transition from one model to another model. The thickness and opacity of the lines
correspond to the number of people following that transition path. Node label sizes correspond to the number of individuals in the model from
the time point. Nodes filled in blue are significantly enriched in pre-travel samples, and nodes in red are significantly enriched in post-travel
samples. The right panel shows the estimates (points) and 95% confidence intervals (lines) for binomial tests of bias for pre- or post-travel
samples. p values for the comparison (FDR-corrected binomial test) are given above the lines. The expected estimate under the null model is
given by the dark black line at 0.5. Source data for all panels is provided in the source data file (Additional file 3)

travel (p=0.7021 [permanova]). This demonstrates
that individuals traveling to the same destination are
far more likely to have their post-travel samples cluster in the same metaresistome than their pre-travel
samples.
Considering these destination signatures, we wanted to
determine if the travelers’ resistomes looked similar to
resident gut resistomes in their travel destinations. We
used shotgun metagenomic reads from a recently published cohort of fecal microbiomes from the Indian subcontinent [58]. After profiling the Indian resistomes

using our ShortBRED AMR protein marker database, we
found that the Dutch subjects returning from Southern
Asia (which includes India) had resistomes that were
more similar to the Indian resistomes compared to subjects returning from the other three subregions (Northern Africa p=2.2e−10; Eastern Africa p<2e−16;
Southeastern Asia p<2e−16 [unpaired Wilcoxon test])
(Additional file 1: Fig. S6 and Additional file 1: Supplementary Note E).
The grouping effect of destination was strongest for
Eastern Africa and Southeastern Asia (Fig. 5b). This
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(See figure on previous page.)
Fig. 4 Travelers to different destinations cluster separately by resistome composition but show similar trends by abundance and diversity metrics.
a The bottom panel shows the comparisons of AMR gene abundance before and after travel to the four subregions in this study. Points
correspond to samples, and boxes give the median and interquartile ranges. Pre-travel is shown in blue, and post-travel is shown in red. The p
values (FDR-corrected paired Wilcoxon tests) for comparisons within the region between the pre- and post-travel samples are shown above each
comparison. The top panel shows the difference between the bootstrapped distributions of the post- and pre-travel samples. The red line gives
the 95% confidence interval for the difference, and the point gives the estimate. b AMR gene α-diversity is measured by richness (left), and
Shannon Index (right) is compared by region between the pre-travel (blue) and post-travel (red) samples. Each point corresponds to a given
sample, and each box gives the median and interquartile range for the distribution. The p values (FDR-corrected paired Wilcoxon test) are above
each comparison. The panels above show the difference between the bootstrapped distributions of the post- and pre-travel samples for each
destination. The red line gives the 95% confidence interval for the difference, and the point gives the estimate. c The left panel compares the βdiversity for pre-travel (blue) and post-travel (red) collections for the four travel destinations. The points are pairwise Bray-Curtis dissimilarity
between two samples, and the boxes represent the median and interquartile ranges of the distributions. p values (paired Wilcoxon test) are given
above each comparison. The right panel shows the difference between the bootstrapped dissimilarities of the pre- and post-travel groups. The
lines give the 95% confidence interval for the difference, and the point gives the estimate. Source data for all panels is provided in the source
data file (Additional file 3)

finding matches the previous results (Fig. 4c) where interindividual resistome β-diversity was lower in subjects
returning from these two destinations. We can see from
these analyses that the destination-specific effects result
in individuals returning from the same destination having similar post-travel resistome states despite diverse
pre-travel states.
AMR gene abundance increases and acquisitions during
travel are concentrated in several AMR gene families and
resistance mechanisms

We found a positive correlation between prevalence and
abundance (p<2e−16) for AMR genes in our Dutch traveler cohort (Additional file 1: Fig. S7), but this correlation varies by AMR mechanism. Efflux (p=6.73e−5),
inactivation (p=2.76e−4), and target protection (p=7.87e
−8) all had significant positive correlations, and the
trend for antibiotic target alteration was also positive. In
contrast, the trend for antibiotic target replacement is
nearly flat, showing that target replacement genes we detected in gut resistomes do not have a corresponding increase in abundance when they are prevalent in more
samples.
We next assessed if the abundance of these mechanisms changed following travel (Fig. 6a). The abundance
of genes encoding for target replacement (p=1.1e−9), efflux (p=3.4e−3), and inactivation (p=8.0e−8) of antibiotics all significantly increased after travel. This indicates
that at the level of AMR mechanisms, there is a significant effect of travel in structuring the gut resistome. By
further classifying the AMR genes families into gene
classes defined by CARD ontology, we observed that 11
of 20 detected classes had increased abundance in the
post-travel samples compared to the pre-travel samples
(Fig. 6b). These data demonstrate that travel-related resistance gene increases are not limited to those identified
by culture-based analysis. The strongest effect was seen
in class A β-lactamases which inactivate several clinically

important antibiotics, though we did not observe class A
carbapenemases. This is consistent with the lack of resistant transformants observed against meropenem in
our functional metagenomic libraries.
We detected 56 AMR genes with significant evidence
of acquisition after travel, compared to only 4 showing
significant loss following travel (Fig. 6c and Additional
file 1: Fig. S8), highlighting the heavy bias of AMR gene
acquisition in the post-travel samples. AMR genes for
antibiotic efflux (p=2.78e−6 [permutation test]) and
for antibiotic target replacement (p=0.0295 [permutation test]) were both highly enriched in the significantly acquired set of genes. In contrast, AMR genes
for antibiotic target protection (p=8.29e−6 [permutation test]) were completely absent in the significantly
acquired genes (far less than predicted under a null
model).
The diversity of AMR genes with significantly increased abundance and acquisition post-travel demonstrates the importance of expanding AMR analysis
beyond ESBLs to the entire gut resistome. For example,
we detected two variants of tetX, an antibioticinactivating monooxygenase which confers resistance
against all clinically relevant tetracyclines, including lastresort antibiotics like tigecycline, eravacycline, and omadacycline [84, 85]. Tetracycline inactivation AMR genes
increased in abundance after travel (Fig. 6b), but the acquisition was only significant for one of two tetX variants (Additional file 1: Fig. S8). The variant of tetX
encoded in NCBI-AMR was not significantly acquired
during travel (0.59 CI [0.406–0.763], p=0.523 [binomial
test]), while the variant of tetX discovered in our functional selections was significantly acquired during travel
(0.75 CI [0.551–0.893], p=0.0247 [binomial test]).
AMR gene acquisitions were also significant when accounting for gene abundance (Additional file 1: Supplementary Note F). Models with taxonomic covariates
(Additional file 1: Fig. S9) built at both the broad AMR
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Fig. 5 Travelers’ resistomes group significantly by region after travel, and Southeastern Asia and Eastern Africa have the strongest signature. a
95% confidence intervals, odds ratios, and p values for the samples with the same destination being drawn from the same metaresistome.
Fisher’s exact tests were done for this comparison within the time point (y-axis). The black vertical line at 1 shows the expected result under the
null. Source data for all panels is provided in the source data file (Additional file 3). b The left of this Sankey diagram has models built from the
pre-travel samples, and the right has models built from the post-travel samples. Each model has a pie chart that shows the number of samples in
the model (total of 190 for each time point), and these pies are divided by destination. The lines connecting the pre- and post-travel models are
colored according to region (dark blue is Northern Africa, light blue is Eastern Africa, orange is Southern Asia, and red is Southeastern Asia), and
their thickness is proportional to the number of samples that follow that path

gene classification level (Additional file 1: Fig. S10-S12)
and at the detailed single-gene level (Additional file 2:
Table S6) all showed more AMR determinants associated with the post-travel time point. A model with all
metadata included identified time point as a significant
predictor of AMR gene abundance for 65 of the 121
AMR genes (Additional file 2: Table S7 and Additional

file 1: Supplementary Note F). Travel duration had a
weak but significant effect on AMR gene acquisition
when all AMR gene acquisitions were considered together (Additional file 1: Fig. S13). When the 121 AMR
genes were considered individually, increased travel duration only significantly correlated with catA, a chloramphenicol acetyltransferase (Additional file 2: Table S7).
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Fig. 6 AMR gene abundance changes and acquisitions are unequal across AMR mechanisms. a AMR mechanism abundance is compared
between pre-travel (blue) and post-travel (red) samples. Each point is a sample, and the boxes represent the median and interquartile range. p
values (FDR-corrected paired Wilcoxon test) for the comparisons are given near the top of the panel. The top panel shows the difference
between the bootstrapped distributions of the post- and pre-travel samples. The lines give the 95% confidence interval for the difference, and
the point gives the estimate. AMR classes where the 95% confidence interval does not cross 0 are red. b AMR class abundance is compared
between pre-travel (blue) and post-travel (red) samples. Each point is a sample, and the boxes represent the median and interquartile range. p
values (FDR-corrected paired Wilcoxon test) for the comparisons are given near the top of the panel. The top panel shows the difference
between the bootstrapped distributions of the post- and pre-travel samples. The lines are the 95% confidence interval for the difference, and the
point is the estimate. AMR classes where the 95% confidence interval does not cross 0 are red. c AMR gene acquisitions or losses after travel.
Each point is an AMR gene, and points are filled in according to their AMR mechanism. The x-axis is the number of individuals that had the gene
in the pre-travel time point, but not in the post-travel time point. The y-axis is the number of individuals that had the gene in the post-travel
time point, but not in the pre-travel time point. The red-shaded region spans significantly acquired AMR genes, the blue-shaded region spans
significantly lost AMR genes, and the gray-shaded region spans genes that were not significantly acquired or lost. The diagonal line is the null of
equal losses and gains for an AMR gene. The inset panel shows which AMR mechanisms were significantly acquired during travel by permutation
testing. The colored histograms show the expected distribution according to 10,000 permutations, and the black vertical lines show the observed
value (points in the red-shaded region of the main plot). The z-score and the FDR-corrected p value for the comparison of observations to their
expected distribution are given in the top left of each plot. Source data for all panels is provided in the source data file (Additional file 3)

Travelers to Southeast Asia had the most AMR gene
acquisition and Southeast Asian functional selections had
high mobile genetic element burden

Every destination showed significant AMR gene acquisition (Fig. 7a), with travelers to Southeastern Asia having
the highest AMR gene acquisition (0.73 CI [0.71–0.75],
p<2e−16) and those visiting Northern Africa having the
lowest AMR gene acquisition (0.67 CI [0.65–0.70], p<2e
−16). Six of the 56 significantly acquired AMR genes
identified in Fig. 6c were significantly associated with
travel destinations (Fig. 7b, c). Travelers to Southeastern
Asia had the most acquisitions normalized by the number of subjects traveling to the region, for all six genes.
Three of these AMR genes were dfrA1 variants, which
confer resistance against trimethoprim. Each dfrA1 variant had a fold change increase between 3.62 and 3.92 in
prevalence in post-travel samples. Increases we saw in
trimethoprim-sulfamethoxazole resistance genes (Figs.
6b and 7c) parallel results from Blyth et al. 2016 where

42% of post-travel E. coli isolates had new resistance
against trimethoprim-sulfamethoxazole [15].
There was a bias for aminoglycoside resistance gene
ant3 to be acquired in Southeastern Asia, and a bias for
the macrolide resistance gene mphA to be acquired in
Southeastern and Southern Asia. tetA was the only AMR
gene of these six with more acquisition events from
Eastern Africa than from Southern Asia though Southeastern Asia still had the highest acquisition rate.
Genomic context like colocalized mobile genetic elements impact AMR gene spread [11, 19, 20, 86]. To
search for AMR gene context, we assembled contigs
from our travelers’ metagenomic samples and searched
for putative mobile genetic element annotations adjacent
to AMR genes. In these AMR-containing contigs, we detected a higher burden of putative mobile genetic elements in post-travel samples than in pre-travel samples
(p=1.4e−10 [paired Wilcoxon test]) (Additional file 1:
Fig. S14A). This difference was significant across all
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Fig. 7 AMR gene acquisitions and mobile genetic elements differed by travel destination. a Significance of AMR gene acquisitions by travel
destination. The lines show the 95% confidence intervals, and the points show the estimates of binomial tests for bias. Binomial tests were
conducted by region for the number of acquired AMR genes and the number of lost AMR genes. Both acquisitions and losses were normalized
by the number of individuals traveling to the region. p values (FDR-corrected) from this test are shown just below the dotted line at 0.5
indicating the null. Numbers lower than 0.5 indicate AMR gene loss, and numbers greater than 0.5 indicate AMR gene gain. b Genes that showed
significant region-specific bias following multinomial testing. Points indicate their number of acquisitions normalized by the number of travel
subjects, and p values are given in the top left. c Sankey diagram of AMR gene acquisitions by travel region. Black nodes are when the gene was
not found, and bright red nodes indicate the gene was present. The width of all lines is proportional to the number of individuals following that
path. d, e The number of MGE elements detected from the functional metagenomic libraries is plotted on the y-axis, and the number of input d
libraries and e reads is on the x-axis. p values calculated by the FDR-corrected multinomial test are in the bottom left of each panel. Most p
values in b, d, and e hit underflow and have been set to p<0.001. Source data for all panels is provided in the source data file (Additional file 3)

regions (Additional file 1: Fig. S14B), but not between
travel destinations (Additional file 1: Fig. S15).
Destination differences did appear when we counted
the number of mobile genetic element-associated annotations on contigs with AMR genes from our functional
metagenomics data. We split these counts based on
sample destination for the inputs to the functional metagenomics selections, and we found a significant association between subregion and the number of mobile
genetic element annotations. This was true when we
normalized by the number of input reads (Fig. 7d) or by
the number of input libraries (Fig. 7e). Travelers to
Southeastern Asia had the most mobile genetic element-

associated annotations despite having fewer input reads
and fewer input libraries. Though travelers to Southeastern Asia had the highest number of mobile genetic elements adjacent to AMR genes, travelers to Southern
Asia and Eastern Africa also had comparable numbers.
Travelers to Northern Africa had far fewer AMR geneassociated mobile genetic element annotations than the
other three regions. This is concordant with our findings
showing that travelers to Northern Africa also had lower
AMR gene abundance and acquisition than other
destinations.
Our results suggest that the colocalization of mobile
genetic elements with AMR genes correlates with
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destination-specific resistance gene acquisition and demonstrate the importance of functional metagenomics
data in detecting these differences. This fact is
highlighted for subregion by the contrast between the
lack of association with travel destination for MGE annotation counts across all assemblies (not necessarily
colocalized with AMR genes) as presented in Additional
file 1: Fig. S15 and the strong association with travel destination in Fig. 7d, e showing annotations in the functional selections where the mobile genetic elements are
adjacent to AMR genes. The number of mobile genetic
elements adjacent to AMR genes may contribute to the
increases in AMR gene burden post-travel.
qPCR detected high-risk AMR genes acquired by Dutch
travelers

Concurrent with our comprehensive metagenomic resistome analysis, we specifically targeted 16 clinically important AMR genes in our samples by qPCR. Of these
16, four genes (tetM, tetQ, ermB, and mefAE) were
present in all of the samples, and two genes (qnrA and
mcr-2) were not present in any samples. We conducted
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acquisition analysis and destination bias analysis for the
remaining 10 genes.
Acquisition analysis showed that 6 of the 10 AMR
genes that were present in at least 1 sample were significantly associated with the post-travel time point (Fig.
8a). Notably, mcr-1, a plasmid borne colistin resistance
gene, was found only in post-travel samples.
Quinolone resistance genes qnrB and qnrS were acquired in high proportion following travel to all four
subregions (Fig. 8b), but blaCTX-M-1, blaCTX-M-9, and
mcr-1 had strong region-specific effects (Figs. 8b and
9a). Over 80% of blaCTX-M-1 and blaCTX-M-9 β-lactamase
acquisitions were in travelers to Asia. blaCTX-M-1 was
predominantly acquired in Southern Asia (61.8%), and
blaCTX-M-9 was predominantly acquired in Southeastern
Asia (82.1%). Uniquely, mcr-1 was only acquired by travelers to Southeastern Asia (Fig. 9a).
Dutch travelers to Southeastern Asia acquired mcr-1

We also observed that AMR genes in our cohort were
often colocalized with mobile genetic elements. mcr-1, a
plasmid-borne colistin resistance gene, was one of the

Fig. 8 Quinolone resistance genes were acquired in regions with equal frequency, while β-lactam resistance genes had destination-specific
acquisition. a AMR genes acquired or lost after travel detected by qPCR. Each point is an AMR gene. The x-axis is the number of individuals that
had the gene in the pre-travel time point, but not in the post-travel time point. The y-axis is the number of individuals that had the gene in the
post-travel time point, but not in the pre-travel time point. Significant acquired AMR genes are in red. The number of significant genes is
tabulated in the top right. Non-significant genes are in black. The diagonal line is the null of equal losses and gains for an AMR gene. The inset
panel gives the results from binomial tests of bias for AMR gene acquisition for the post-travel time point. The lines are 95% confidence intervals,
and the points are estimates. p values (FDR-corrected binomial test) are given at the bottom of the plot for each gene. The dotted line is the
expected value under the null. The lines and points are red if significantly acquired. b Sankey diagrams of significant gene acquisitions by travel
region detected by qPCR. Black nodes are when the gene was not found, and bright red nodes indicate the gene was present. Ribbon colors
correspond to the destination countries (dark blue is Northern Africa, light blue is Eastern Africa, orange is Southern Asia, and red is Southeastern
Asia). The width of all lines is proportional to the number of individuals following that path. Source data for both panels is provided in the source
data file (Additional file 3)
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Fig. 9 mcr-1 containing contig from a Dutch traveler matched a plasmid sequenced from a gastroenteritis patient in the destination region. a
Sankey network showing region-specific acquisition for mcr-1. b Map showing where the reference genome was isolated from a gastroenteritis
patient. c Alignment between a plasmid from an E. coli isolated from a gastroenteritis patient in Chiang Mai and a contig assembled from a
Dutch traveler’s gut microbiome. Source data for all panels is provided in the source data file (Additional file 3)

most concerning genes we detected. Colistin is a drug of
last resort for drug-resistant gram-negative pathogens
used when other antimicrobial therapies fail [87, 88].
mcr-1 is the first plasmid-borne resistance gene against
colistin, and it is responsible for rapidly increasing colistin resistance observed over the last 4–5 years [20].
Eighteen of the 52 Dutch travelers to Southeastern Asia
(34.6%) acquired mcr-1 during our study.
To further investigate the mcr-1 colistin resistance
gene, we assembled contigs using the raw shotgun
reads from the samples that were mcr-1 positive by
qPCR and annotated these contigs for mcr-1. One
contig assembled from subject S032, a traveler returning from Vietnam, was positive (Fig. 9). Plasmidfinder
2.0 identified subject S032’s mcr-1 containing contig
as an IncI2 type plasmid (100% identity and 100%
template length using the Enterobacteriaceae database) [89, 90]. A follow-up study [91] of the 6 isolates
from Arcilla et al. [92] demonstrated that one ESBLproducing E. coli from a traveler returning from
Vietnam also harbored mcr-1 on an IncI2 type
plasmid.
We searched NCBI for the best BLAST match of subject S032’s mcr-1 containing contig, and the top hit

(99.9% identity with 100% query coverage) was to a plasmid from gastroenteritis-causing E. coli (Fig. 9b) isolated
in Chiang Mai, Thailand (data from BioSample SAMN1
0531954 and NCBI reference sequence NZ_CP034405.1
). In both plasmids (Fig. 9c), mcr-1 is flanked by a tra
cluster of conjugon transfer genes, and mcr-1 is also
colocalized with a virB cluster type IV secretion system
(T4SS). T4SS have known involvement in horizontal
gene transfer [93–97]. There are prior reports of mcr-1
colocalization with T4SS in plasmids [20, 98], though in
those studies mcr-1 was on different plasmid incompatibility types than IncI2.

Discussion
Global AMR spread threatens decades of success in
treating bacterial infections with antibiotics [6, 10, 99–
101]. This problem is exacerbated by the worldwide
spread of antibiotic-resistant bacteria and AMR genes by
international travelers [8, 102]. Our investigation of 190
Dutch individuals’ gut resistomes before and after travel
indicates international travel is a significant gut resistome perturbation and highlights the extent of AMR
gene acquisition. We found the acquisition of previously
unknown, functionally discovered AMR genes, increased
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AMR gene abundance, and increased resistome αdiversity in the post-travel samples. We also observed
AMR gene colocalization with mobile genetic elements
and identified travel destination-specific resistome
signatures.
A study by Langelier et al. in 2019 reported on the
resistome in 10 travelers to Asia or Africa [103]. Eight of
these travelers went to Nepal, one went to Nigeria, and
one went to Uganda. The authors sampled the subjects
once before travel and thrice after travel; they found increased AMR genes against multiple antibiotic classes,
including β-lactams, quinolones, and anti-folates. This
increase in AMR genes after travel mirrors our results,
and many of the AMR genes they identified were also
detected in our study. Interestingly, in contrast to the results in Langelier et al., we saw increases in some tetracycline resistance genes and aminoglycoside resistance
genes after travel. For the tetracycline resistance genes,
this may be explained by our more detailed consideration of the resistance mechanism. We observed that
while tetracycline inactivation mechanisms significantly
increased in abundance after travel, tetracycline ribosomal protection mechanisms did not. In fact, none of the
tetracycline ribosomal protection resistance genes was
significantly acquired during travel. Our study-specific
functional metagenomic selection database also provides
higher sensitivity to detect AMR genes that may be underrepresented in conventional AMR databases. Indeed,
51 of the 121 (42.1%) AMR genes detected and compared in our analysis were from functional selections.
The AMR genes identified in Langelier et al. are often
found in commonly cultured clinical isolates and thus
are well represented in conventional AMR databases.
An individual’s gut resistome response to travel perturbation may parallel the response from other nontravel gut perturbations, including hospitalization and
antimicrobial treatment [104, 105]. In a 2017 study of
healthy patients compared to antibiotic-treated patients
hospitalized in an ICU in The Netherlands, Buelow et al.
found that healthy patients had enriched tetW and catA
[105]; both tetW and catA were also more likely to be
found in our pre-travel than post-travel samples. In contrast, the antibiotic-treated ICU patient resistomes in the
Buelow et al. study were enriched for AMR genes such
as erm and an aac(6’) family gene, both of which were
also acquired and increased in our post-travel samples.
With antibiotic perturbation, the effects on the gut resistome can vary based on the spectrum of the antibiotic
[41, 42, 81]. However, studies commonly observe an increase in resistome α-diversity and a decrease in βdiversity [81]. This is similar to our observations in response to travel perturbation. Additionally, some studies
show a time dependence for AMR gene acquisitions and
abundance increases [42, 81] paralleling the weak time
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dependence we show in our results. There are conflicting results if these antibiotic perturbations return to the
initial state or leave persistent scars [42, 106]. Even if the
travel-related resistome changes revert to baseline, it is
possible that the AMR genes will be disseminated in the
resident country before they are lost in the host.
The high-risk gene acquisitions we observed are concordant with qPCR-based research of endemic antibiotic
resistance in our cohort’s travel destinations. In 2019,
Bich et al. demonstrated qnr endemicity in Vietnam with
100% carriage of qnr by qPCR of fecal samples from 93
Vietnamese residents of the Ha Nam province [107].
This same study also found carriage of blaCTX-M-1 (38%)
and blaCTX-M-9 (61%). These results correspond well
with both the high acquisition rate we saw for these
genes in individuals returning from Southeastern Asia
and the blaCTX-M-9 predominance we saw in travelers
returning from Southeastern Asia.
Our cohort’s mcr-1 Southeast Asian geographic acquisition bias is also consistent with Bich et al. where 88%
of tested Vietnamese residents carried mcr-1 [107]. In
comparison, a culture-based study [92] by Arcilla et al.
of ESBL-producing E. coli isolates from all 2001 participants (540 to Southeastern Asia) in the COMBAT study
detected mcr-1 in 6 E. coli isolates, indicating higher detection sensitivity for mcr-1 using qPCR directly from
the stool. These results are also comparable to another
culture-based isolate study [27] where 20 of 412 returning US travelers yielded mcr-harboring E. coli.
In 2018, Wang et al. analyzed mcr-1-containing plasmids across a number of different bacterial isolates from
around the globe [11]. China and Vietnam were the two
countries with the most isolates harboring mcr-1 plasmids, which corresponds to our detection of mcr-1 in
travelers to Southeastern Asia. The authors found that
mcr-1 initially mobilized to plasmids through an ISApl1
transposon. This is consistent with the reference plasmid
in Fig. 9c.
Our mcr-1 results advocate for a combined approach
of AMR gene detection. Short-read shotgun metagenomic sequencing provided us with excellent data for
understanding gut resistome composition changes, diversity changes, and AMR gene acquisitions due to
travel, but only 1 of 18 (5.6%) mcr-1 qPCR-positive stool
samples we assembled yielded an mcr-1 contig. However, we show that AMR gene contig assembly yields an
important genomic context surrounding resistance genes
that could have implications for understanding and
modeling AMR gene spread. Contig assembly using
short-read shotgun metagenomic sequencing may differ
by AMR gene. For example, we successfully assembled
tetX in 56 of 143 (39.2%) ShortBRED-positive samples.
Future studies may employ chromosome conformation
capture or long-read sequencing in concert with short-
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read sequencing to improve metagenomic assembly and
give even more detailed genomic context to resistance
gene detection directly from stool [28].
Our study design was optimized to understand the acquisition within travelers, and we do not have samples
from travelers’ contacts while abroad. Pre-travel samples from our Dutch cohort also contain resistant
bacteria and AMR genes, but our study is only
equipped to show unidirectional gene transfer from
the destination to the travelers; it is also possible
that travelers could deposit AMR genes in their
travel destinations. Future investigation into travelers’
contacts at home and abroad may resolve AMR gene
transmission networks. We also observed that grouping samples by subregion better explains the sample
composition than grouping by continent. It is possible that we are missing even more granular effects
that would be found at the country or even city level
[40, 108].

Conclusions
We provide new data regarding the effect of international travel to low- and middle-income regions on
the gut resistome of travelers from a high-income country. We show that such travelers acquire AMR genes
abroad and carry these AMR genes back to their countries of origin. These AMR genes include both known
clinically relevant AMR genes that are common in pathogens (e.g., blaCTX-M and mcr-1) and functionally discovered AMR genes with no known homologs in the
current databases. We also show AMR gene acquisition
and carriage in the gut resistome is travel destinationspecific with compositional signatures lasting at least
until the traveler returns home. Interventions to reduce AMR burden in low- and middle-income countries with current high endemic AMR burdens may
reduce traveler AMR gene acquisitions. Developments
in risk stratification for AMR genes could help target
such efforts [109].
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